Drug Profile
TMG 123
Alternative Names: TMG-123Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Jun 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Japan (PO) (Teijin Pharma pipeline, June 2021)
- 24 Sep 2020 No development reported - Phase-II for Type 2 diabetes mellitus in Japan (PO) (Teijin Pharma website, September 2020)
- 31 Aug 2018 Teijin Pharma completes a phase II trial in Type-2 diabetes mellitus in Japan (PO) (JapicCTI173698)